Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.33 |
| ▸ | BCL2 | P10415 | 3/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480070 | 0.95 | EGLN1 (0.33) | EGLN1BCL2BCL2L1MCL1PTGDR | |
| SCHEMBL3480485 | 0.88 | BCL2 (0.33) | EGLN1BCL2BCL2L1MCL1PTGDR | |
| SCHEMBL3931183 | 0.87 | EGLN1 (0.33) | EGLN1 | |
| SCHEMBL3480114 | 0.86 | PTGDR (0.34) | EGLN1PTGDRPTGDR2 | |
| SCHEMBL13021136 | 0.85 | EGLN1 (0.32) | EGLN1 | |
| SCHEMBL3919835 | 0.83 | MCL1 (0.36) | BCL2BCL2L1MCL1 | |
| SCHEMBL3480483 | 0.83 | BCL2 (0.33) | EGLN1BCL2BCL2L1MCL1TRPV4 | |
| SCHEMBL3480318 | 0.81 | XDH (0.33) | EGLN1TRPV4 | |
| SCHEMBL4138497 | 0.79 | MCL1 (0.36) | BCL2BCL2L1MCL1 | |
| SCHEMBL12979512 | 0.77 | XDH (0.33) | EGLN1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | claimed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | EGLN1 3579/4885BCL2 4620/4885BCL2L1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.